Unidad de Investigación Clínica de Cáncer de Próstata

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Cáncer de Próstata

Vacante Director

Investigador Clínico I

  • Elena Castro

Prostate cancer is the most common cancer diagnosis in men and, despite its potential to be cured in almost 90% of early stages, its metastatic spread causes about 6,000 deaths every year in Spain alone, whilst in the US over 30,000 men succumb to the disease each year.

During the last few years, our Group has focused precisely on the development of new methods to identify and treat the most aggressive and lethal forms of prostate cancer, in order to accelerate precision medicine for the disease. In particular, over the last 8 years, our group has made significant contributions in:

  1. Establishing and developing several biomarkers based on the concept of liquid biopsy.
  2. Understanding the implication of gene alterations leading to DNA repair deficiency in this disease.
  3. Developing new treatments for prostate cancer.

Our work has been widely recognised with several highly cited publications in top journals in our field, including The New England Journal of Medicine, The Lancet Oncology, The Journal of Clinical Oncology, European Urology, Annals of Oncology, and many others.